• In May 2026, IDEXX Laboratories expanded its Fecal Dx antigen testing to include taeniid tapeworms and integrated the SDMA kidney biomarker into Catalyst CLIPs for U.S. and Canadian veterinary customers at no additional cost.
• These upgrades deepen IDEXX’s role in earlier parasite and kidney disease detection, potentially increasing the clinical reliance on its diagnostic platforms.
• Next, we’ll examine how embedding SDMA into Catalyst CLIPs may influence IDEXX’s investment narrative built around recurring diagnostics growth.

Uncover the next big thing with 23 elite penny stocks that balance risk and reward.

IDEXX Laboratories Investment Narrative Recap

To own IDEXX, you need to believe that higher diagnostic use per vet visit and expanding test menus can support recurring revenue, even if clinic traffic stays soft. The latest SDMA and Fecal Dx upgrades look directionally helpful to that thesis but do not clearly change the near term catalyst of consumables growth or the key risk that slower instrument placements and visit pressure could eventually cap that growth.

The SDMA integration into Catalyst CLIPs is the most relevant development here, because it embeds an advanced kidney marker into one of IDEXX’s most widely used in clinic chemistry profiles. If clinicians routinely run SDMA without extra friction or cost, that could further anchor IDEXX’s position in point of care testing and support its recurring diagnostics narrative, especially if it counterbalances any slowdown tied to softer U.S. visit trends.

Yet even with these product upgrades, investors should be aware that pressure on visit volumes and premium pricing could still...

IDEXX Laboratories' narrative projects $5.2 billion revenue and $1.3 billion earnings by 2028. This requires 8.8% yearly revenue growth and about a $300 million earnings increase from $985.7 million today.

Uncover how IDEXX Laboratories' forecasts yield a $750.23 fair value, a 33% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimating analysts were already cautious, assuming about US$5.5 billion of revenue and US$1.4 billion of earnings by 2029, and they frame innovation like SDMA integration alongside concerns about clinic volumes and pricing power as a much more pessimistic path than the consensus, which is why it is worth weighing these contrasting views yourself.

Explore 3 other fair value estimates on IDEXX Laboratories - why the stock might be worth just $552.08!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your IDEXX Laboratories research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free IDEXX Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate IDEXX Laboratories' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.
• This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.